Skip to content

Depression research published in 2016

107 studies whose primary subject is depression were published in 2016, up from 72 in 2015. Newest first. Back to the depression overview

Studies

A Mindfulness-Based Intervention Pilot Feasibility Study for Elementary School Students With Severe Learning Difficulties: Effects on Internalized and Externalized Symptoms From an Emotional Regulation Perspective.

Journal of Evidence-Based Complementary & Alternative Medicine December 30, 2016 Catherine Malboeuf-Hurtubise, Éric Lacourse, Geneviève Taylor et al.

Objective: Students with severe learning disabilities often show signs of anxiety, depression, and problem behaviors such as inattention and conduct problems. Mindfulness-based interventions (MBIs) in school settings constitute a promising option to alleviate these co-occurring symptoms. This pilot study aimed to evaluate the impact of an MBI on symptoms and behaviors of elementary school...

Abnormal Time Experiences in Major Depression: An Empirical Qualitative Study

Psychopathology December 15, 2016 Giovanni Stanghellini, Massimo Ballerini, Simona Presenza et al. 115 citations

BACKGROUND: Phenomenological psychopathology, through theoretical and idiographic studies, conceptualizes major depressive disorder (MDD) as a disorder of time experience. Investigations on abnormal time experience (ATE) in MDD adopting methodologies requested by the standards of empirical sciences are still lacking. Our study aimed to provide a qualitative analysis, on an empirical ground and...

DOI: 10.1159/000452892 (opens in new tab) Major depressive disorder Schizophrenia object-oriented programming Psychopathology Depression economics +2

Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder

The Journal of Clinical Psychiatry December 6, 2016 Jennifer L. Vande Voort, Elizabeth D. Ballard, David A. Luckenbaugh et al. 67 citations

OBJECTIVE: Insomnia and disrupted sleep are associated with increased risk of suicide. The N-methyl-d-aspartate antagonist ketamine has been associated with reduced suicidal thoughts, but the mechanism of action is unknown. This study sought to evaluate differences in nocturnal wakefulness in depressed individuals who did and did not have an antisuicidal response to ketamine. METHODS:...

Continuation phase intravenous ketamine in adults with treatment-resistant depression.

Journal of Affective Disorders December 2016 Jennifer L. Vande Voort, Robert J Morgan, Simon Kung et al.

Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5mg/kg, administered...

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Neuroscience Bulletin December 2016 Weili Zhu, Zengbo Ding, Yinan Zhang et al.

Major depression is a serious psychiatric disorder and remains a leading cause of disability worldwide. Conventional antidepressants take at least several weeks to achieve a therapeutic response and this lag period has hindered their ability to attain beneficial effects in depressed individuals at high risk of suicide. The non-competitive N-methyl-D-aspartate glutamate receptor antagonist...

Return of the psychedelics: Psilocybin for treatment resistant depression.

Asian Journal of Psychiatry December 1, 2016 Suravi Patra

Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. The efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this...

[Ketamine administration in case of severe, therapy resistant depressed patient, case report].

Ideggyogyaszati szemle November 30, 2016 Szabolcs Morvai, Attila István Nagy, Adrienn Bálint-Szöllősi et al.

Objective - In our case report we present the treatment of a female patient suffering from therapy resistant depression. This procedure is not in practice in Hungary at present, the aim of our work to reproduce the findigs of international studies in domestic circumstances. Matter - Major depression is a common, chronic and severe mental disorder, with 16.2% lifetime prevalence. Many...

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Journal of Psychopharmacology November 30, 2016 Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al. 1,699 citations

Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were...

DOI: 10.1177/0269881116675512 (opens in new tab) Anxiety Depression Cancer Psychedelic therapy psilocybin +6

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Journal of Psychopharmacology November 30, 2016 Annie Umbricht, Mary P Cosimano, Roland R. Griffiths et al. 2,174 citations

Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the...

Continuous Social Defeat Induces Depression-Like Symptoms Including Anhedonia and Slowed Time Perception that are Rapidly Reversed by Ketamine

Timing & Time Perception November 26, 2016 Bin Yin, Sven Thönes, Ruey-Kuang Cheng et al.

Male Sprague–Dawley rats were exposed to social defeat and subordination by aggressive male Long–Evans rats. The social defeat procedure involved the continuous exposure to an aggressive resident for 10 days, while living in a protective cage within the resident’s home cage with daily brief confrontations. These stress experiences resulted in 1) reduced body weight; 2) decreased social...

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Journal of Psychopharmacology November 18, 2016 James Rucker, Luke A. Jelen, Sarah Kalen Flynn et al. 187 citations

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used...

Guided Intervention through Scientific Method of Meditation for Management of Stress and Depression among College Students

International Journal of Science and Research (IJSR) November 11, 2016 Dr. M. K. Bimal, D. Vimal

Introduction: The study was conducted to explore and manage depression, stress and anxiety among college students by providing guided intervention of scientific spiritual method of AUM meditation. Plan of study: The plan of study included objective mapping of reduction in comprehensive anxiety and enhancement in mental health after intervention with scientific spiritual meditation for 30 days....

S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression

The International Journal of Neuropsychopharmacology November 2, 2016 Maryam Ardalan, Gregers Wegener, Ali H. Rafati et al. 38 citations

Background: The neurovascular plasticity of hippocampus is an important theory underlying major depression. Ketamine as a novel glutamatergic antidepressant drug can induce a rapid antidepressant effect within hours. In a mechanistic proof of this concept, we examined whether ketamine leads to an increase in synaptogenesis and vascularization within 24 hours after a single injection in a...

Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.

Drug Development Research November 2016 Vesna Pešić, Jelena Petrović, Marin M Jukić

Preclinical Research The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of...

Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression.

Hippocampus November 2016 Maryam Ardalan, Gregers Wegener, Benedetta Polsinelli et al.

Glutamatergic system and the structural plasticity hypothesis are principal components for rapid and sustained antidepressant effects of novel antidepressant therapeutics. This study represents the first investigation of the structural plasticity of the hippocampus as one of the main contributed mechanisms to the sustained anti-depressive effect of ketamine. Flinders Sensitive Line (FSL) and...

Psychological and neuropsychological assessment of regular hoasca users.

Comprehensive Psychiatry November 1, 2016 Paulo César Ribeiro Barbosa, Rick J. Strassman, Dartiu Xavier Da Silveira et al. 104 citations

Hoasca (also called ayahuasca) is a N,N-dimethyltryptamine (DMT) - containing psychedelic brew originally used for magico-religious purposes by Amerindian populations of the Amazon Basin. Recently, Brazilian syncretic churches have helped spread the ritual use of hoasca to Western societies. The aim of this study was to evaluate substance use, and neuropsychological and psychological...

Role of psilocybin in the treatment of depression

Therapeutic Advances in Psychopharmacology October 27, 2016 Ananya Mahapatra, Rishi Gupta 37 citations

Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating...

Mindfulness Training for Health Profession Students-The Effect of Mindfulness Training on Psychological Well-Being, Learning and Clinical Performance of Health Professional Students: A Systematic Review of Randomized and Non-randomized Controlled Trials.

Explore October 24, 2016 Janet C. McConville, Rachael McAleer, Andrew J. Hahne

Background: High levels of stress have been identified in medical students and increasingly in other health profession student population groups. As stress can affect psychological well-being and interfere with learning and clinical performance, there is a clear argument for universities to include health professional student well-being as an outcome in core curriculum. Mindfulness training is...

Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2016 Yong‐Ku Kim, Kyoung-Sae Na

Treatment-resistant depression (TRD) causes substantial socioeconomic burden. Although a consensus on the definition of TRD has not yet been reached, it is certain that classic monoaminergic antidepressants are ineffective for TRD. One decade ago, many researchers found ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, to be an alternative to classic monoaminergic antidepressants....